TSHA-102 clinical trial results featured by Taysha Gene Therapies at Child Neurology Society Annual Meeting

TSHA-102 clinical trial results featured by Taysha Gene Therapies at Child Neurology Society Annual Meeting
Taysha showcases TSHA-102 research

Taysha Gene Therapies announced it will present multiple encore presentations supporting its TSHA-102 clinical program for Rett syndrome at the 55th Annual Meeting of the Child Neurology Society.

The company is aiming to advance the development of TSHA-102 as a potential gene therapy for patients with Rett syndrome. These presentations are intended to provide updates and reinforce clinical data for the investigational program.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.